Raymond J. Furey

Executive

Rigel Pharmaceuticals IncMallinckrodt plc

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 1 saleMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (12 ops.)

€2.1M

Latest filing published 03 Sept 2026 for RIGEL PHARMACEUTICALS INC, €36k.

Filing timeline

BuySale

Raymond J. Furey

Insider track record

Disclosed buys

Disclosed sells

Signal history

Raymond J. Furey: trading record in brief

Raymond J. Furey has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Mallinckrodt plc, Rigel Pharmaceuticals Inc and Questcor Pharmaceuticals Inc. Over a trading history stretching from 23 May 2013 to 1 September 2026, the count stands at 47 filings.

No open-market purchase appears, only 12 sales worth €2.1M. Besides market trades, the filings include 28 share grants and 4 option exercises.

The newest entry dates from 3 September 2026: a share grant of €36k, in Rigel Pharmaceuticals Inc. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.